Literature DB >> 27738762

Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.

Tsuyoshi Hamada1, NaNa Keum2, Reiko Nishihara3,4,5,6, Shuji Ogino7,8,9,10.   

Abstract

Molecular pathological epidemiology (MPE) is an integrative field that utilizes molecular pathology to incorporate interpersonal heterogeneity of a disease process into epidemiology. In each individual, the development and progression of a disease are determined by a unique combination of exogenous and endogenous factors, resulting in different molecular and pathological subtypes of the disease. Based on "the unique disease principle," the primary aim of MPE is to uncover an interactive relationship between a specific environmental exposure and disease subtypes in determining disease incidence and mortality. This MPE approach can provide etiologic and pathogenic insights, potentially contributing to precision medicine for personalized prevention and treatment. Although breast, prostate, lung, and colorectal cancers have been among the most commonly studied diseases, the MPE approach can be used to study any disease. In addition to molecular features, host immune status and microbiome profile likely affect a disease process, and thus serve as informative biomarkers. As such, further integration of several disciplines into MPE has been achieved (e.g., pharmaco-MPE, immuno-MPE, and microbial MPE), to provide novel insights into underlying etiologic mechanisms. With the advent of high-throughput sequencing technologies, available genomic and epigenomic data have expanded dramatically. The MPE approach can also provide a specific risk estimate for each disease subgroup, thereby enhancing the impact of genome-wide association studies on public health. In this article, we present recent progress of MPE, and discuss the importance of accounting for the disease heterogeneity in the era of big-data health science and precision medicine.

Entities:  

Keywords:  Colorectal neoplasms; Drug therapy; Immunology; Microbiology; Personalized therapy

Mesh:

Year:  2016        PMID: 27738762      PMCID: PMC5325774          DOI: 10.1007/s00535-016-1272-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  149 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 2.  Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.

Authors:  Li Zhou; Kui Wang; Qifu Li; Edouard C Nice; Haiyuan Zhang; Canhua Huang
Journal:  Expert Rev Proteomics       Date:  2016-03-16       Impact factor: 3.940

3.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

4.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Juhong Yang; Kosuke Mima; Annacarolina da Silva; Yan Shi; Kentaro Inamura; Yin Cao; Mingyang Song; Jonathan A Nowak; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott Rodig; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Gut       Date:  2016-05-05       Impact factor: 23.059

Review 5.  Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.

Authors:  Malgorzata E Wojtowicz; Barbara K Dunn; Asad Umar
Journal:  Semin Oncol       Date:  2015-11-14       Impact factor: 4.929

Review 6.  Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored.

Authors:  Stephen K H Li; Alberto Martin
Journal:  Trends Mol Med       Date:  2016-03-09       Impact factor: 11.951

7.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Authors:  Marie Vétizou; Jonathan M Pitt; Romain Daillère; Patricia Lepage; Nadine Waldschmitt; Caroline Flament; Sylvie Rusakiewicz; Bertrand Routy; Maria P Roberti; Connie P M Duong; Vichnou Poirier-Colame; Antoine Roux; Sonia Becharef; Silvia Formenti; Encouse Golden; Sascha Cording; Gerard Eberl; Andreas Schlitzer; Florent Ginhoux; Sridhar Mani; Takahiro Yamazaki; Nicolas Jacquelot; David P Enot; Marion Bérard; Jérôme Nigou; Paule Opolon; Alexander Eggermont; Paul-Louis Woerther; Elisabeth Chachaty; Nathalie Chaput; Caroline Robert; Christina Mateus; Guido Kroemer; Didier Raoult; Ivo Gomperts Boneca; Franck Carbonnel; Mathias Chamaillard; Laurence Zitvogel
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

8.  Molecular pathological epidemiology gives clues to paradoxical findings.

Authors:  Reiko Nishihara; Tyler J VanderWeele; Kenji Shibuya; Murray A Mittleman; Molin Wang; Alison E Field; Edward Giovannucci; Paul Lochhead; Shuji Ogino
Journal:  Eur J Epidemiol       Date:  2015-10-07       Impact factor: 8.082

Review 9.  Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review.

Authors:  Łukasz Szylberg; Marlena Janiczek; Aneta Popiel; Andrzej Marszałek
Journal:  Gastroenterol Res Pract       Date:  2015-04-07       Impact factor: 2.260

10.  Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors.

Authors:  Matthew Frampton; Richard S Houlston
Journal:  Genet Med       Date:  2016-08-04       Impact factor: 8.822

View more
  50 in total

Review 1.  Human microbiome and prostate cancer development: current insights into the prevention and treatment.

Authors:  Solmaz Ohadian Moghadam; Seyed Ali Momeni
Journal:  Front Med       Date:  2020-06-30       Impact factor: 4.592

2.  Post-colonoscopy colorectal cancer: the key role of molecular pathological epidemiology.

Authors:  Tsuyoshi Hamada; Reiko Nishihara; Shuji Ogino
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-15

Review 3.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

Review 4.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

5.  Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Yohei Masugi; David A Drew; Mingyang Song; Yin Cao; Keisuke Kosumi; Kosuke Mima; Tyler S Twombly; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; Katsuhiko Nosho; NaNa Keum; Marios Giannakis; Jeffrey A Meyerhardt; Kana Wu; Molin Wang; Andrew T Chan; Edward L Giovannucci; Charles S Fuchs; Reiko Nishihara; Xuehong Zhang; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

6.  Cancer subtypes in aetiological research.

Authors:  Lorenzo Richiardi; Francesco Barone-Adesi; Neil Pearce
Journal:  Eur J Epidemiol       Date:  2017-05-11       Impact factor: 8.082

Review 7.  Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Danny A Milner; Reiko Nishihara
Journal:  Annu Rev Pathol       Date:  2018-08-20       Impact factor: 23.472

Review 8.  Advancing precision medicine with personalized drug screening.

Authors:  Kirill Gorshkov; Catherine Z Chen; Raisa E Marshall; Nino Mihatov; Yong Choi; Dac-Trung Nguyen; Noel Southall; Kevin G Chen; John K Park; Wei Zheng
Journal:  Drug Discov Today       Date:  2018-08-17       Impact factor: 7.851

9.  Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status.

Authors:  Akiko Hanyuda; Yin Cao; Tsuyoshi Hamada; Jonathan A Nowak; Zhi Rong Qian; Yohei Masugi; Annacarolina da Silva; Li Liu; Keisuke Kosumi; Thing Rinda Soong; Iny Jhun; Kana Wu; Xuehong Zhang; Mingyang Song; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Reiko Nishihara
Journal:  Eur J Epidemiol       Date:  2017-05-16       Impact factor: 8.082

10.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.